Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
The company’s matching strategy for CB-010 will soon be put to the test.
Vobra-duo is discontinued at long last.
